

# Perceptions of Olanzapine Tolerability & Adverse Event Mitigation Strategies in Real-World Practice




Quantitative survey of N=437 US psychiatric clinicians; patient/caregiver input included<sup>1</sup>

Clinicians rated their perceived safety/tolerability of olanzapine versus other antipsychotics with mean sentiment scores. Each response was valued at -1 for "less safe/tolerable than olanzapine," 0 for "comparable," and +1 for "more safe/tolerable." Unsure responses were excluded.<sup>1</sup>

## Clinician Perceptions of Tolerability


Perceived Safety/Tolerability for the Treatment of Adult Patients With Schizophrenia, Not Considering Efficacy or Potential Outcomes<sup>1</sup>



Clinicians rate OLZ less favorable on weight/metabolic/sedation; more favorable on prolactin/EPS vs select APs.


## What Triggers Weight Gain Mitigation Strategies?<sup>2</sup>

For patients who gain weight while taking olanzapine, how would you rank the following factors when deciding whether strategies to mitigate weight gain are warranted?




## How Clinicians Ranked Weight Gain Mitigation Strategies?<sup>2</sup>

Which of the following would be your plan to mitigate weight gain with olanzapine?



## Clinician Ratings of Medications to Help Mitigate Weight Gain Associated With Olanzapine<sup>2</sup>


For a patient gaining weight on olanzapine, how would you prefer the following medications be used?



After metformin, clinicians showed no large preference among Lybalvi, GLP-1 agonists, or topiramate.

## Clinician Ranking of Mitigation Strategies to Address Weight Gain Associated With Olanzapine<sup>2</sup>

Which of the following would be the typical plan at your practice to mitigate weight gain with olanzapine?




Medication to mitigate weight gain stood out as the top approach overall. However, no mitigation method was consistently viewed as highly effective overall.

## Patient & Caregiver Perceptions<sup>3</sup>

Patient and Caregiver Ratings for Addressing Olanzapine-Related Weight Gain<sup>3</sup>


How have you/has the person living with schizophrenia addressed OLZ-related weight gain?



<sup>3</sup>An online survey of 84 patients with schizophrenia and 85 caregivers, including patients on at least one antipsychotic, gathered data on treatment experiences, perceptions of olanzapine's effectiveness and tolerability, and barriers to use.

## Clinician Ratings on Strategies for Addressing Adverse Events<sup>2</sup>


HCP responses on addressing potential adverse events with olanzapine




Clinicians most commonly treat sedation and metabolic effects via dose reduction.

## HCP Ratings of the Potential Barriers Associated With the Available LAI Olanzapine<sup>4</sup>

How significant are each of the following barriers to your ability to utilize the currently available long-acting injectable olanzapine for your adult patients with schizophrenia?



Clinicians were asked to rate their level of agreement with the following statements: (N=437)



## Abbreviations

AP, antipsychotic; EPS, extrapyramidal symptoms; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1; HCP, health care provider; LAI, long-acting injectable; mgmt, management; REMS, Risk Evaluation and Mitigation Strategies; OLZ, olanzapine; PCP, primary care provider; PDSS; post-injection delirium/sedation syndrome.

## References

- Hansen R, et al. Clinician Perspectives on the Efficacy and Safety/Tolerability of Olanzapine Compared With Other Antipsychotics: Results From the SONAR (Survey on Olanzapine Needs and Attitudes Research) Study. Poster presented at: European College of Neuropsychopharmacology (ECNP) Congress, October 11-14, 2025; Amsterdam, The Netherlands.
- Hansen R, et al. Clinician Perspectives on Olanzapine-Associated Adverse Event Mitigation Strategies for Schizophrenia Treatment: Results From the SONAR (Survey on Olanzapine Needs and Attitudes Research) Study. Poster presented at: Psych Congress 2025; September 17-21, 2025; San Diego, CA, USA.
- Data on File (Clinical Study Report, Patients and Caregivers). Parsippany, NJ. Teva Neuroscience, Inc.
- Hansen R, et al. Clinician Perspectives on Long-Acting Injectable Olanzapine Treatment Barriers and Unmet Need From the SONAR (Survey on Olanzapine Needs and Attitudes Research) Study. Poster presented at: Psych Congress 2025; September 17-21, 2025; San Diego, CA, USA.

For educational purposes only. Educational materials were provided as a service by Teva Pharmaceuticals Medical Affairs. Not for redistribution. © 2026 Teva Neuroscience, Inc. | SDS-US-NP-00096 | 03/26